Mandate of BaFin’s special commissioner at flatexDEGIRO terminated
Mandate of BaFin’s special commissioner at flatexDEGIRO terminated
The mandate of the BaFin’s special commissioner at flatexDEGIRO Bank AG (the “Company”) was terminated on September 30, 2024, following the successful elimination of the serious deficiencies identified in the 2022 special audit by the Company and a positive review by the special commissioner. flatexDEGIRO AG made this announcement on October 18, 2024, following a corresponding decision by the German Federal Financial Supervisory Authority (BaFin).
Oliver Behrens, CEO of flatexDEGIRO, said: “We have realigned and sustainably strengthened our organizational structures and processes in constructive cooperation with BaFin and the special commissioner. We are thereby closing a regulatory chapter and again increase our focus on our customers and important growth projects. My special thanks go to all employees who, under the leadership of Steffen Jentsch, member of the bank's management board, have made it possible to reach this important milestone.”
Dr. Benon Janos, Deputy CEO & CFO of flatexDEGIRO, added: “In a comparatively short period of two years and with a strong team effort, we have successfully addressed the deficiencies. The solutions we have implemented go beyond the regulatory requirements in some cases.”
About flatexDEGIRO AG
flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR) operates one of the leading and fastest growing online brokerage platforms in Europe. Based on modern, in-house state-of-the-art technology, customers of the flatex and DEGIRO brands are offered a wide range of independent products with execution on top TIER 1 exchanges. The technological edge, high efficiency and strong economies of scale enable flatexDEGIRO to continuously improve its service offering for clients and set leading standards in terms of product, price and platform quality.
With around 3 million customer accounts and around 60 million securities transactions processed in 2023, flatexDEGIRO is one of the largest retail online brokers in Europe. In times of bank consolidation, low real interest rates and digitalization, flatexDEGIRO is ideally positioned for further growth.
Further information can be found at https://www.flatexdegiro.com/en.
| Language: | English |
| Company: | flatexDEGIRO AG |
| Omniturm, Große Gallusstraße 16-18 | |
| 60312 Frankfurt / Main | |
| Germany | |
| Phone: | +49 (0) 69 450001 0 |
| E-mail: | ir@flatexdegiro.com |
| Internet: | www.flatexdegiro.com |
| ISIN: | DE000FTG1111 |
| WKN: | FTG111 |
| Indices: | SDAX |
| Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241018441467/en/
Contacts
Achim Schreck Phone +49 (0) 69 450001 1700
Head of IR & Corporate Communications achim.schreck@flatexDEGIRO.com
Laura Hecker Phone +49 (0) 160 3064 404
Director Investor Relations laura.hecker@flatexdegiro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biological Lattice Industries (BLI) Secures $1.8 Million Pre-Seed Funding Led by Uni.Fund to Democratize Biofabrication18.10.2024 17:00:00 EEST | Press release
Biological Lattice Industries Corp. (BLI), a leading innovator in biofabrication and life sciences R&D, today announced the successful closing of a $1.8 million pre-seed investment round led by Greek venture capital firm Uni.Fund. In conjunction with this funding announcement , BLI is introducing its first all-in-one solution for biofabrication: BioLoom™, BLI's advanced multi-tool 3D bioprinter and Loominus Studio™, its unified software platform designed to revolutionize biofabrication workflows. BLI, a US startup with R&D operations in Greece, aims to radically simplify biofabrication for the global R&D community by providing intelligent, automated tools that streamline the design, fabrication, and testing of biomaterials. Biomaterials are critical for a wide array of biological applications. The applications range from advanced 3D cell culture systems for human biology emulation to the next-generation of resorbable medical devices and drug delivery systems for tissue trauma repair. “
Gurobi Brings Decision Intelligence Summit to Amsterdam18.10.2024 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is set to host the first annual EMEAI Decision Intelligence Summit (“Gurobi Summit”) at Amsterdam’s Capital C on November 5-6, 2024. Following the success of last month’s inaugural summit for the Americas in Las Vegas, the EMEAI Summit will bring together operations researchers, data scientists, and business leaders from across the region to explore the latest advancements in mathematical optimization and decision intelligence. The Gurobi Summit will feature special presentations from companies such as Accenture and ICRON. Several of the company’s partners—including Decide4AI, Decision Labs, LTPLabs, and ORMAE—will also be present to showcase their solutions and insights. The two-day event will be packed with informative presentations, exciting customer case studies, and interactive learning opportunities. Day 1 will feature keynotes, technical presentations, and panel discussions. Day 2 will be dedicated to hand
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting18.10.2024 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024 in Philadelphia, Pennsylvania. Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy” will be presented as an oral presentation on Sunday, October 20, during the “Best Abstract” session, which runs from 8:00-11:00 a.m. ET, as well as the Education session which runs on Monday, October 21, from 1:30-2:30 p.m. ET. Abstract A2074 — “A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions” will be present
SLB Announces Third-Quarter 2024 Results18.10.2024 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the third quarter of 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241016795721/en/ The exterior of the SLB headquarters in Houston, Texas. (Photo: Business Wire) Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2024Jun. 30, 2024Sept. 30, 2023SequentialYear-on-yearRevenue $9,159 $9,139 $8,310 - 10% Income before taxes - GAAP basis $1,507 $1,421 $1,395 6% 8% Income before taxes margin - GAAP basis 16.5% 15.5% 16.8% 91 bps -33 bps Net income attributable to SLB - GAAP basis $1,186 $1,112 $1,123 7% 6% Diluted EPS - GAAP basis $0.83 $0.77 $0.78 8% 6% Adjusted EBITDA* $2,343 $2,288 $2,081 2% 13% Adjusted EBITDA margin* 25.6% 25.0% 25.0% 55 bps 54 bps Pretax segment operating income* $1,902 $1,854 $1,683 3% 13% Pretax segment operating margin* 20.8% 20.3% 20.3% 48 bps 51 bps Net income attributable to SLB, excluding charges & cr
MDPI Champions Open Access for Global Progress18.10.2024 11:00:00 EEST | Press release
MDPI, a leading open access (OA) publisher, is proud to announce its participation in International Open Access Week 2024, 21–27 October. This year’s theme, “Community over Commercialization”, resonates with MDPI’s commitment to publishing insights for everyone, regardless of background. OA Week is a valuable opportunity to inspire engagement with the open access movement and to advocate for more sustainable and inclusive scholarly communication. This mission, shared by MDPI, helps to ensure that all communities have the means to participate in shaping global futures. To support these aims, MDPI will be sharing a variety of digital resources discussing quality and ethics in OA publishing, the tools we provide to support researchers, and the benefits of OA and open research. For more information on MDPI’s initiatives, please visit our website. By working together to further open access, we can collectively contribute to democratizing knowledge sharing among the global research community
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom